Core Viewpoint - Xinda Biologics (01801) reported strong financial results for the six months ending June 30, 2025, with significant revenue growth and a return to profitability, driven by robust performance in its oncology product line and expansion of its product portfolio [1][2]. Financial Performance - The company achieved revenue of RMB 5.953 billion, a year-on-year increase of 50.6% [1] - Net profit reached RMB 834 million, marking a return to profitability compared to the previous period [1] - Basic earnings per share were RMB 0.51 [1] - Non-IFRS profit increased to RMB 1.213 billion, reflecting ongoing improvements in operational efficiency [1] Product Performance - Product revenue amounted to RMB 5.234 billion, representing a year-on-year growth of 37.3% [1] - The oncology product portfolio maintained a leading advantage, with strong performance from major products and continuous contributions from new product revenues [1] - The company successfully commercialized five new drugs during the reporting period, expanding its product portfolio to 16 products [2]
信达生物绩后高开逾4% 上半年利润8.34亿元 肿瘤产品组合领先优势稳固